Oxaliplatin, 5-Fluorouracil, and Folinic Acid (Folfox) in Patients With Metastatic Renal Cell CarcinomaResults of a Pilot Study
作者:
Malika Chaouche,
Alain-Louis Pasturaud,
Didier Kamioner,
Michel Grandjean,
Jacques Franiatte,
Jean-Marc Tourani,
期刊:
American Journal of Clinical Oncology: Cancer Clinical Trials
(OVID Available online 2000)
卷期:
Volume 23,
issue 3
页码: 288-289
ISSN:0277-3732
年代: 2000
出版商: OVID
关键词: 5-Fluorouracil;Immunotherapy;Oxaliplatin;Renal cell carcinoma.
数据来源: OVID
摘要:
We report the results of a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and folinic acid in patients with metastatic renal cell carcinoma. The objective of this pilot study was to define the potential efficacy of this second-line combination in patients previously treated with interleukin-2 alone or in combination with interferon alpha. Fourteen patients with metastatic renal cell carcinoma in failure after immunotherapy were included in this trial. During treatment, patients received six chemotherapy courses (Folfox regimen) administered every 2 weeks. Each cycle combined oxaliplatin day (D) D1 and folinic acid plus 5-fluorouracil D1 and D2. At completion of treatment, no objective response was observed and two patients presented stable disease. This chemotherapy schedule in patients with metastatic renal cell carcinoma previously treated with immunotherapy does not seem to be effective.
返 回